Discontinued — last reported Q3 '21
Business Segments · Operating Income
Pharmaceutical Distribution Services — Operating Income
Cencora Pharmaceutical Distribution Services — Operating Income decreased by 2.5% to $472.06M in Q3 2021 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2014
Last reportedQ3 2021
Rolls up toOperating Income
How to read this metric
Higher operating income indicates improved margins, cost control, or favorable product mix shifts.
Detailed definition
The profit earned from the pharmaceutical distribution segment's core operations after deducting operating expenses such...
Peer comparison
Key metric for comparing operational efficiency against peers like McKesson and Cardinal Health.
Metric ID:
cor_segment_pharmaceutical_distribution_services_operating_incomeHistorical Data
2 periods
| Q2 '21 | Q3 '21 | |
|---|---|---|
| Value | $483.91M | $472.06M |
| QoQ Change | — | -2.5% |
Range$472.06M – $483.91M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Cencora's pharmaceutical distribution services — operating income?
- Cencora (COR) reported pharmaceutical distribution services — operating income of $472.06M in Q3 2021.
- What does pharmaceutical distribution services — operating income mean?
- The profit generated by the distribution segment before interest and taxes.